12/10-2017 08:00:16: (BGBIO) Clinical Study with BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, to be Presented at the 9th World Congress of Melanoma
Bergen, Norway, Oct 12 2017 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective Axl kinase inhibitors for
multiple cancer indications, announces that the clinical trial of BGB324 in
combination with either MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or
KEYTRUDA® in advanced melanoma, will be presented at the 9th World Congress of
Melanoma in Brisbane, Australia, October 18-21, 2017.
Dr. Oddbjørn Straume, consultant oncologist at Haukeland University Hospital and
Professor at the University of Bergen Centre for Cancer Biomarkers will present
a poster entitled: A Phase Ib/II randomised study of BGB324 in combination with
pembrolizumab or dabrafenib/trametinib in patients with advanced melanoma. The
presentation will introduce the trial design and study background as well as
present safety data of metastatic melanoma patients treated to date.
· Poster number P12-10 - Brisbane Convention & Exhibition Centre, October 18 -
For more information visit: https://www.melanomacongress.com/
About BerGenBio ASA
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on
developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple
cancer indications. The Company is a world leader in understanding the essential
role of Axl kinase in mediating cancer spread, immune evasion and drug
resistance in multiple aggressive solid and haematological cancers.
BerGenBio's lead product, BGB324, is a selective, potent and orally bio
-available small molecule Axl inhibitor in four Company sponsored Phase II
clinical trials in major cancer indications, with read-outs anticipated in the
second half of 2018. It is the only selective Axl inhibitor in clinical
The Company sponsored clinical trials are:
1. BGB324 as a single agent and combination therapy in acute myeloid leukaemia
(AML) / myeloid dysplastic syndrome (MDS)
2. BGB324 with TARCEVA® (erlotinib) in advanced EGFR mutation driven non-small
cell lung cancer (NSCLC)
3. BGB324 with KEYTRUDA® (pembrolizumab) in advanced adenocarcinoma of the
4. BGB324 with KEYTRUDA in triple negative breast cancer (TNBC).
The clinical trials combining BGB324 with KEYTRUDA in adenocarcinoma of the lung
and TNBC are conducted in collaboration with Merck & Co. Inc. (MSD).
In addition, a number of investigator-sponsored trials are underway, including a
trial to investigate BGB324 with either MEKINIST® (trametinib) plus TAFINLAR®
(dabrafenib) or KEYTRUDA in advanced melanoma, as well as a trial combining
BGB324 with docetaxel in advanced NSCLC.
BerGenBio is simultaneously developing a companion diagnostic test to identify
patient subpopulations most likely to benefit from treatment with BGB324. This
will facilitate more efficient registration trials and support a precision
medicine based commercialisation strategy.
The Company is also developing a diversified pre-clinical pipeline of drug
candidates, including BGB149, an anti-AXL monoclonal antibody.
For further information, please visit: www.bergenbio.com
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary
of Merck & Co., Inc., Kenilworth, NJ, USA, TARCEVA® is a registered trademark of
OSI Pharmaceuticals, LLC., marketed by Roche-Genentech. TAFLINAR® is a
registered trademark of Novartis International AG and MEKINIST® is a registered
trademark of GSK plc.
CEO, BerGenBio ASA
+47 917 86 304
Tom Henrik Sundby
Finance Director, BerGenBio ASA
+47 477 54 415
David Dible, Mark Swallow, Marine Perrier
Citigate Dewe Rogerson
+44 207 638 9571
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
Ekstern link: http://www.newsweb.no/index.jsp?messageId=436276
Nyheten er levert av OBI.